MJA
MJA

Substance-related disorders

Consensus statement

Consensus recommendations on the management of hepatitis C in Australia's prisons

Rebecca J Winter, Yumi Sheehan, Timothy Papaluca, Graeme A Macdonald, Joy Rowland, Anton Colman, Mark Stoove, Andrew R Lloyd and Alexander J Thompson

Med J Aust 2023; 218 (5): 231-237 Free

Research letter

Non‐fatal opioid overdose after release from prison among men who injected drugs prior to their imprisonment: a prospective data linkage study

Michael Curtis, Paul Dietze, Rebecca J Winter, Kasun Rathnayake, Karen Smith and Mark Stoove

Med J Aust 2023; 218 (2): 94-95 Free

Letters

What doctors should consider before prescribing e‐liquids for e‐cigarettes

Colin P Mendelsohn and Carolyn Beaumont

Med J Aust 2022; 217 (10): 547-547

Letters

What doctors should consider before prescribing e‐liquids for e‐cigarettes

Alexander Larcombe, David Chapman and Miranda Ween

Med J Aust 2022; 217 (10): 548-548

Perspectives

Twenty‐one years at the Uniting Medically Supervised Injecting Centre, Sydney Australia: addressing the remaining questions

Carolyn A Day, Allison Salmon, Marianne Jauncey, Mark Bartlett and Amanda Roxburgh

Med J Aust 2022; 217 (8): 385-387 Free

Narrative review

Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient‐centred multidisciplinary care

Lucy O Attwood, Megan McKechnie, Olga Vujovic, Peter Higgs, Martyn Lloyd‐Jones, Joseph S Doyle and Andrew J Stewardson

Med J Aust 2022; 217 (2): 102-109 Free

Editorials

Responding to the rising number of suicides using barbiturates

Bridin P Murnion and Darren M Roberts

Med J Aust 2022; 216 (4): 187-188

Medical education / Snapshot

Vision loss and methamphetamine use

Yi Fan Tang and Elaine Chong

Med J Aust 2022; 216 (2): 72-72

Letters

Screening and brief interventions for harmful alcohol use: where to now?

Jana Malinovská and Jan Brož

Med J Aust 2021; 215 (11): 525-525

Letters

Screening and brief interventions for harmful alcohol use: where to now?

Chris B Holmwood

Med J Aust 2021; 215 (11): 526-526

Guideline summary

Revision of the Australian guidelines to reduce health risks from drinking alcohol

Katherine M Conigrave, Robert L Ali, Rebecca Armstrong, Tanya N Chikritzhs, Peter d’Abbs, Mark F Harris, Nicole Hewlett, Michael Livingston, Dan I Lubman, Anne McKenzie, Colleen O’Leary, Alison Ritter, Scott Wilson, Melanie Grimmond and Emily Banks

Med J Aust 2021; 215 (11): 518-524 Free

Medical education / Lessons from practice

Poppy seed tea dependence requiring depot buprenorphine treatment

Shalini Arunogiri, Rowan Dowling, Vicky Phan, Michelle Sharkey, Temika Mu and Dan I Lubman

Med J Aust 2021; 215 (11): 504-505

Research

Barbiturate‐related hospitalisations, drug treatment episodes, and deaths in Australia, 2000‒2018

Shane Darke, Agata Chrzanowska, Gabrielle Campbell, Emma Zahra and Julia Lappin

Med J Aust 2022; 216 (4): 194-198 Free

Editorials

Treatment of alcohol problems: current status and future directions

Paul S Haber, Benjamin C Riordan and Kirsten C Morley

Med J Aust 2021; 215 (7): 315-316 Free

Letters

Greater scrutiny needed of alcohol companies’ use of brand extensions

Hannah Pierce and Julia Stafford

Med J Aust 2021; 215 (7): 334-335.e1

Letters

Recreational nitrous oxide misuse is resulting in serious neurological impairment and persistent disability among users

Simon Mosalski, Anne Tanner and Christine T Shiner

Med J Aust 2021; 215 (5): 237-237.e1

Editorials

Opioid prescribing in Australia: too much and not enough

Adrian J Dunlop, Buddhima Lokuge and Nicholas Lintzeris

Med J Aust 2021; 215 (3): 117-118 Free

Letters

Buprenorphine: extended‐release formulations “a game changer”!

Katerina Lagios

Med J Aust 2021; 214 (11): 534-534.e1

Perspectives

When will opioid agonist therapy become a normal part of comprehensive health care?

Pallavi Prathivadi and Elizabeth A Sturgiss

Med J Aust 2021; 214 (11): 504-505.e1

Letters

Rapid detection, toxicosurveillance and public health response to stimulant adulteration with acetyl fentanyl

Varan Perananthan, Chris Tremonti, Emily Nash, Thanjira Jiranantakan and Andrew H Dawson

Med J Aust 2021; 214 (11): 533-533.e1

Editorials

The challenges of managing both chronic pain and opioid use in general practice

Hester Wilson

Med J Aust 2021; 214 (9): 416-417

Perspectives

Should we be routinely co‐prescribing naloxone for patients on long term opioids?

Pallavi Prathivadi and Suzanne Nielsen

Med J Aust 2021; 214 (9): 403-404.e1

Letters

The impact of Victoria’s real time prescription monitoring system (SafeScript) in a cohort of people who inject drugs

Dagnachew M Fetene, Peter Higgs, Suzanne Nielsen, Filip Djordjevic and Paul Dietze

Med J Aust 2021; 214 (5): 234-234.e1

Letters

The impact of Victoria’s real time prescription monitoring system (SafeScript) on a cohort of people who inject drugs

Malcolm Dobbin

Med J Aust 2021; 214 (5): 234-234.e1

Perspectives

What are people saying on social networking sites about the Australian alcohol consumption guidelines?

Benjamin C Riordan, Daniel T Winter, Paul S Haber, Carolyn A Day and Kirsten C Morley

Med J Aust 2021; 214 (3): 105-107.e1